[针对日本患有转移性割抵抗性前列腺癌患者的综合基因组分析测试:单一机构的经验]
Shiori Miyachi1, Takeshi Sasaki1, Momoko Kato1
1The Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine.
Hinyokika kiyo. Acta urologica Japonica
|July 6, 2025
概括
综合性基因组分析有效地确定了日本患有转移性割抵抗性前列腺癌 (mCRPC) 的患者的基因变异. 使用下一代测序的组织和液体活检几乎在所有情况下都检测到致病变体,包括BRCA1/2变化.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子诊断学 分子诊断学
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...